Table 2.
Laboratory investigations
| Diabetic subjects n = 67 |
Control subjects n = 65 |
p value | |
|---|---|---|---|
| Glucose (mmol/l) | 6.8 (5.6–8.0) | 5.3 (4.8–5.6) | <0.001 |
| Total cholesterol (mmol/l) | 4.91 (4.18–5.39) | 4.53 (3.89–5.41) | 0.40 |
| Triglycerides (mmol/l) | 1.55 (1.21–1.96) | 1.48 (1.10–1.79) | 0.25 |
| HDL cholesterol (mmol/l) | 1.24 (1.09–1.48) | 1.31 (1.12–1.52) | 0.29 |
| LDL cholesterol(mmol/l) | 2.89 (2.42–3.64) | 2.75 (2.32–3.57) | 0.33 |
| Platelets (×103/mm3) | 213 (177–248) | 219 (179–253) | 0.69 |
| Creatinine (μmol/L) | 77 (43–172) | 84 (43–154) | 0.42 |
| CRP (mg/l) | 2.60 (1.65–4.41) | 2.34 (1.64–4.33) | 0.28 |
| Fibrinogen (g/l) | 4.43 (3.45–4.96) | 3.87 (3.18–4.82) | 0.037 |
| PAI-1 (ng/ml) | 65.4 (47.9–78.0) | 27.0 (21.4–35.0) | <0.001 |
| TAFI (%) | 103 (93–117) | 106 (99–113) | 0.76 |
| tPA (ng/ml) | 10.4 (9.0–11.1) | 7.9 (6.5–9.9) | <0.001 |
| vWF (IU/ml) | 108 (100–129) | 108.0 (100–119) | 0.31 |
| sCD40L (ng/ml) | 1.04 ± 0.24 | 0.97 ± 0.27 | 0.10 |
| P-selectin (ng/ml) | 199.4 ± 34.3 | 175.1 ± 39.8 | <0.001 |
| Ks (10−9cm2) | 7.70 ± 1.34 | 8.20 ± 0.92 | 0.02 |
| t50% (min) | 9.42 ± 1.47 | 8.94 ± 1.23 | 0.04 |
Data are shown as X ± SD or median (IQR)
HDL high-density lipoprotein, LDL low-density lipoprotein, CRP C-reactive protein, PAI-1 plasminogen activator inhibitor-1, TAFI thrombin activatable fibrinolysis inhibitor, tPA tissue plasminogen activator, vWF von Willebrand factor, sCD40L soluble CD40 ligand, K s permeation coefficient, t 50% clot lysis time